BioSpace News Archive

Essilor: Capital Increase Reserved for Employees Outside France

Employee shareholding is central to Essilor’s history, identity and culture.

October 26, 2017

·

4 min read

Biotech Beach

ROX Medical Announces Sustained Improvements in Patients With Uncontrolled Hypertension Treated With the ROX Coupler

ROX Medical announced the publication of 12-month outcomes of the ROX CONTROL HTN study in the prestigious journal, Hypertension.

October 26, 2017

·

2 min read

Business

Catalyst Biosciences Announces the Appointment of Industry Veteran Andrea Hunt to its Board of Directors

Ms. Hunt was most recently vice president, New Product Gene Therapy, Neuroscience, Oncology, Ophthalmology at Shire.

October 26, 2017

·

3 min read

Business

Genocea to Host Third Quarter 2017 Financial Results Conference Call & Webcast on November 2, 2017 at 9 a.m. ET

Genocea management will also provide an update on the Company’s recent progress and upcoming milestones.

October 26, 2017

·

1 min read

BioMidwest

IDT’s 2017 Sustainability Award Funding to Exceed $50K

Demonstrating its ongoing commitment to science advocacy and sustainability, Integrated DNA Technologies (IDT), is inviting applications for its 2017 Sustainability Award program.

October 26, 2017

·

3 min read

Drug Development

Atara Biotherapeutics Receives Rare Pediatric Disease Designation From FDA for ATA230 for Treatment of Congenital Cytomegalovirus (CMV) Infection

The FDA grants Rare Pediatric Disease designation to drugs or biologics intended to treat serious or life-threatening rare diseases that primarily affect individuals aged from birth to 18 years and fewer than 200,000 persons in the U.S.

October 26, 2017

·

6 min read

Business

MyoKardia to Announce Third Quarter 2017 Financial Results on Thursday, November 2, 2017

Management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss these results and provide a business update.

October 26, 2017

·

2 min read

Drug Development

Innovation Pharmaceuticals Aims to Develop First Drug for Approval in Prevention of Oral Mucositis in Head and Neck Cancer Patients as Phase 2 Clinical Trial of Brilacidin Completes

The final patient in the Phase 2 randomized, placebo-controlled clinical trial completed their post-therapy follow-up examination this week.

October 26, 2017

·

7 min read

BioMidwest

BioSig Technologies Announces Results of Independent Product Assessment Study for PURE EP System

BioSig Technologies today announced that the Company has concluded a key part of the strategic planning project launched earlier this year in collaboration with Health Research International (HRI).

October 26, 2017

·

3 min read

Deals

Neos Therapeutics to Review Unsolicited Proposal From PDL BioPharma

Neos Therapeutics, Inc. today confirmed that it has received an unsolicited proposal from PDL BioPharma, Inc. to acquire all of the outstanding shares of Neos for $10.25 per share in cash.

October 26, 2017

·

3 min read